PRMT5 and cancer: As shown in Fig. 6a, b, protein expression of GLI1 was reduced by MEP50 or PRMT5 knockdowns, suggesting that MEP50/PRMT5-mediated activation of HH signalling operates in HH-expressing cancer cells.